Sorafenib for the treatment of multiple myeloma. Gentile M et al. Expert Opin Investig Drugs. 2016 Mar 21. [Epub ahead of print]. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma. Gibiansky L et al. J Pharmacokinet Pharmacodyn. 2016 Mar 18. [Epub ahead of print]. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. Rotolo A et al. Br J Haematol. 2016…
Multiple myeloma cancer stem cells. Gao M et al. Oncotarget. 2016 Mar 17. doi: 10.18632/oncotarget.8154. [Epub ahead of print]. Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Tang M et al. Clin Cancer Res. 2016 Mar 22. pii: clincanres.2793.2015. [Epub ahead of print]. Multiple myeloma in the marrow: pathogenesis and treatments. Fairfield H et al. Ann N Y…
Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Sonneveld P et al. Blood. 2016 Mar 21. pii: blood-2016-01-631200. [Epub ahead of print]. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. Wahaib K et al. Am J Health Syst Pharm. 2016 Apr 1;73(7):441-50. doi: 10.2146/ajhp150487. Haematological cancer: PomCyDex – a lower-cost option in refractory myeloma?…
Multiple myeloma presenting with acute bony spinal cord compression and mechanical instability successfully managed non-operatively. Gokaraju K et al. Spine J. 2016 Mar 17. pii: S1529-9430(16)00456-3. doi: 10.1016/j.spinee.2016.03.011. [Epub ahead of print]. Is balloon kyphoplasty safe and effective for cancer-related vertebral compression fractures with posterior vertebral body wall defects? Molloy S et al. J Surg Oncol. 2016 Mar 21. doi: 10.1002/jso.24222. [Epub…
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Dimopoulos MA et al. J Clin Oncol. 2016 Mar 14. pii: JCO650044. [Epub ahead of print]. Myeloma of the central nervous system – an ongoing conundrum! Harrison SJ et al. Leuk Lymphoma. 2016 Mar 21:1-2. [Epub ahead of print]. A case of multiple myeloma presenting as a distal renal tubular acidosis with extensive…
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Moreau P et al. Blood. 2016 Mar 21. pii: blood-2016-01-693580. [Epub ahead of print]. Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib? Gozzetti A et al. Br…
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Nishihori T et al. Curr Hematol Malig Rep. 2016 Feb 22. [Epub ahead of print]. Fully automated classification of bone marrow infiltration in low-dose CT of patients with multiple myelomabased on probabilistic density model and supervised learning. Martínez-Martínez F et al. Comput Biol Med. 2016 Feb 8;71:57-66. doi: 10.1016/j.compbiomed.2016.02.001. [Epub ahead of print].…
Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics. Sundararajan S et al. Curr Hematol Malig Rep. 2016 Feb 19. [Epub ahead of print]. Clinical characteristics and outcomes in biclonal gammopathies. Mullikin TC et al. Am J Hematol. 2016 Feb 3. doi: 10.1002/ajh.24319. [Epub ahead of print]. Trachyonychia as the presenting sign of myeloma-associated amyloidosis. Shim JH et al. Int J Dermatol. 2016 Feb 12. doi: 10.1111/ijd.13240. [Epub…
A practical review on carfilzomib in multiple myeloma. Muchtar E et al. Eur J Haematol. 2016 Feb 19. doi: 10.1111/ejh.12749. [Epub ahead of print]. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going Thanendrarajan S et al. Immunotherapy. 2016 Feb 17. [Epub ahead of print]. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple…
USO1 promotes tumor progression via activating Erk pathway in multiple myeloma cells. Jin Y et al. Biomed Pharmacother. 2016 Mar;78:264-71. doi: 10.1016/j.biopha.2016.01.012. Epub 2016 Feb 2. Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats. Al-Harbi NO et al. Toxicol Mech Methods. 2016 Feb 21:1-7. [Epub ahead of print]. Distinct lncRNA transcriptional fingerprints characterize progressive stages…